Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac and respiratory endpoints. For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have been deployed over 30,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 70% of all FDA drug approvals since 2012.

For more information, go to Clario.com or follow us on LinkedIn.

TesoRx Pharma and its subsidiary, Lipac Oncology, are clinical-stage companies utilizing a novel Neoliposomal™ delivery system. This delivery system addresses significant challenges like poor solubility, low permeability, and systemic toxicity, creating breakthrough therapies. Their primary clinical candidates are for intracavitary carcinomas (Lipac) and oral Testosterone Replacement Therapy (TRT) (TesoRx). TesoRx's TRT bypasses the liver via lymphatic absorption, demonstrating clinically enhanced bioavailability.

RheoTek Medical is advancing ultra-precise drug delivery technologies—needle and needle-free—designed to enhance accuracy, consistency, and patient outcomes across immunotherapy, vaccines, and pain management. Our platform addresses the critical need for controlled dosing and predictable delivery, expanding access to life-saving therapies and enabling new treatment possibilities in both clinical and decentralized settings.

Amcor is a global leader in packaging solutions for consumer and healthcare products. With industry-leading innovation capabilities, global scale and technical expertise, we help our customers grow and meet the needs of millions of consumers every day. Our teams develop responsible, more sustainable packaging in flexible and rigid formats across multiple materials. Supported by a commitment to safety, ~70,000 colleagues across ~140 countries bring our global capabilities to local customers and provide local access to global brands. Our work is guided by our purpose of elevating customers, shaping lives and protecting the future. NYSE: AMCR; ASX: AMC

Imagine Pharma is a biotechnology company focused on the development of its IMG-1® polypeptide. Research and development efforts have led to the creation of three distinctive platforms for Oral Delivery, Therapeutics, and Regenerative Medicine. Each platform comprises first-in-class programs that address multiple disease states in large, underserved markets.

Working, creating, together. We are convinced that in a world where new medicines, new practices and better therapeutic outcomes are constantly being sought, collaboration is the only way to efficiently reach these goals. Nanomi has developed the unique Microsieve technology that adds value to drug development programs of others. The technology is applicable to a wide range compounds and provides the most advanced solution for manufacture of uniform monodisperse biodegradable microspheres and nanoparticles for long-acting release medicines. Nanomi’s pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare. Nanomi is open to partnerships.

Ossianix Inc has developed highly selective and potent brain shuttles. We use the single domain VNAR antibody platform targeting the transferrin receptor and the amino acid transporter CD98 to produce industry leading brain shuttles that deliver therapeutic levels of a broad range of drugs to the CNS including antibodies, enzymes, peptides and oligonucleotides (ASO& siRNA). Our lead oligo programs are MAPT and alpha synuclein for neurodegenerative disease which are in pre clinical development.

Nelson Labs is a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. We serve over 3,000 customers from 12 facilities in the United States, Mexico, Asia and Europe and offer a comprehensive array of over 900 laboratory tests along with the expertise of Regulatory Compliance Associates, a recognized leader in regulatory consulting for the life sciences industry. We support our customers from initial product development and sterilization validation, through regulatory approval and ongoing product testing for sterility, safety and quality assurance.  We are regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues. Safeguarding Global Health® – with every test completed. Learn more: nelsonlabs.com.

Founded in 1927, Littelfuse is a diversified industrial technology manufacturing company empowering a more sustainable, connected, and safer world. Across more than 20 countries, and with approximately 16,000 global associates, we partner with customers to design and deliver innovative, reliable application solutions. Littelfuse offers an extensive technology portfolio— switches, sensors, TVS diodes, diode arrays, fuses, semiconductors, polymers, ceramics, relays, and more. Serving over 100,000 end customers, our products are found in a variety of health care, electronics, and mobile end markets— everywhere, every day. Littelfuse offers solutions for various health care applications, including auto-injectors or drug delivery pens, Continuous Glucose Monitors (CGM), insulin pumps, and wearable injectors. Discover how Littelfuse components and system modeling can optimize your designs for cost-effective, high-performance medical devices. Visit us at Booth #611 to stay ahead in medical innovation.

Intrepid Labs accelerates drug formulation using AI, automation, and deep pharmaceutical expertise. Our proprietary platforms combine automated experimentation and machine learning to rapidly design, optimize, and characterize drug products. We partner with pharma and biotech to solve complex formulation challenges. Founded in 2023, Intrepid is building a data-driven, scalable, and patient-focused future for drug development.

PenPal® seamlessly integrates exceptional design simplicity with superior performance, reliability, and platform versatility. Our vision is to leverage our capabilities and innovative PenPal® autoinjector technology to support pharmaceutical and biopharmaceutical partners in need of high-performance autoinjectors. We are dedicated to addressing underserved market segments that require injection dose volumes larger than 2.25 ml and/or high-viscosity formulations.

Founded in 2018, TruTechnologies is the leading provider of real-time clinical trial oversight, focused on enabling timely, high-quality data and mitigating risks in drug development. The company partners with six top 20 pharmaceutical companies and numerous biotechnology firms to accelerate patient screening and enrollment, drive protocol adherence, and correct deviations. For more information, please visit www.trutechnologies.io